PHVS - Pharvaris Pharma Total Debt to Capital

Reliable pharmaceutical logistics stabilize the price action of Pharvaris N.V. (PHVS), ensuring uninterrupted patient access to therapy. The business foundation relies on the introduction of tablet deucrictibant to capture market share and recession resilience driven by the specific product cycle. This debt-to-equity financing structure chart demonstrates a leverage level where 0.00 serves as the baseline value for the company's indebtedness parameter.

An investment audit of the issuer requires a thorough review of the balance sheet structure before purchasing the asset. This ratio is calculated as the sum of all liabilities divided by equity, measuring the level of financial leverage. For Pharvaris N.V. (PHVS), which utilizes an outsourcing model without its own manufacturing plants, high indebtedness is critical due to its reliance on external contractors. The current total debt-to-equity ratio allows for an assessment of insolvency risk. The trend of this indicator determines the overall stability of the business model.